In 2023, a single 12-week Phase II trial in adults with obesity produced a body weight reduction that, until then, had only been described after bariatric surgery. The intervention was not a surgical procedure. It was a once-weekly subcutaneous injection of a synthetic peptide that activates three metabolic receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). The compound is retatrutide, and the trial results — published in the New England Journal of Medicine and indexed on PubMed — have made it the most closely watched molecule in metabolic research since tirzepatide. For South African researchers and informed readers, BioMuti supplies Retatrutide 30mg as a research-grade peptide vial, independently tested for identity and purity.
Retatrutide's appeal is not just the magnitude of weight loss observed in trials. It is what the trial represents structurally: the first time a single peptide has been engineered to engage three distinct class B1 G-protein-coupled receptors (GPCRs) in a defined stoichiometry, and to do so safely in humans for an extended dosing period. Tirzepatide, the dual GIP/GLP-1 agonist, set the stage; retatrutide is the next layer in what is rapidly becoming a polypharmacological design space for metabolic disease. Understanding how retatrutide works, what the trial data show, and where the research is heading requires a careful look at each of its three targets in turn.
The Three Receptors: GIP, GLP-1, and Glucagon
All three receptors retatrutide engages belong to the class B1 GPCR family — a structural class that also includes receptors for parathyroid hormone, calcitonin, and corticotropin-releasing factor. Class B1 receptors share a distinctive extracellular domain that binds the C-terminal region of their peptide ligands, and a transmembrane domain that transmits the conformational change to intracellular G-proteins. GIPR, GLP-1R, and GCGR are expressed in overlapping but distinct tissue distributions: GIPR most abundantly on pancreatic alpha and beta cells and on adipose tissue; GLP-1R on pancreatic beta cells, the hypothalamus, the gut, and certain vagal afferents; GCGR primarily on hepatocytes and on pancreatic alpha cells, with lower expression in the kidney, adrenal gland, and selected CNS nuclei.
The three receptors couple primarily to Gs proteins, raising intracellular cyclic AMP on activation, but the downstream consequences differ. GLP-1R activation suppresses glucagon secretion, slows gastric emptying, and reduces appetite through hypothalamic and brainstem circuits. GIPR activation amplifies glucose-stimulated insulin secretion and, in adipose tissue, modulates lipid storage and possibly bone turnover. GCGR activation, paradoxically given its name, increases energy expenditure and lipolysis — at least when engaged in the right tissue at the right intensity. The pharmacology of these three receptors individually is reviewed on PMC.
The therapeutic insight underlying retatrutide is that layering glucagon receptor agonism on top of GIP and GLP-1 agonism does not simply add the effects; it produces complementary effects on energy balance. GLP-1R agonism reduces appetite and food intake. GIPR agonism improves insulin sensitivity and may reduce adipose inflammation. GCGR agonism raises resting energy expenditure and promotes hepatic lipid oxidation. Combine them in one molecule, and the three effects reinforce each other rather than cancelling each other out — provided the GCGR activity is held below the threshold that would produce overt hyperglycaemia. Retatrutide's design is, in effect, a dose-titrated polypharmacology.
The Molecular Design of Retatrutide
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide with a C20 fatty diacid moiety conjugated via a linker to a lysine residue, mirroring the albumin-binding strategy that gave tirzepatide its five-day half-life. The amino acid sequence is a hybrid: positions 2 and 13 are derived from GIP (as in tirzepatide), but additional residues are modified to confer GCGR activity while preserving GIPR and GLP-1R potency. In vitro, retatrutide activates GIPR with potency comparable to native GIP, GLP-1R with potency slightly lower than semaglutide, and GCGR with potency approximately one-fifth of native glucagon — a deliberately attenuated GCGR signal designed to maximise the metabolic benefits of glucagon agonism (energy expenditure, hepatic lipid turnover) while minimising its dominant liability (glycogenolysis-driven hyperglycaemia).
The pharmacokinetic profile supports once-weekly subcutaneous dosing. Steady-state concentrations are reached within four to six weeks of initiation, and the terminal half-life is approximately six days — slightly longer than tirzepatide, which is consistent with the additional fatty-acid modifications made to fine-tune albumin binding. The structural biology and receptor pharmacology are detailed in the original phase I characterisation, indexed on PubMed.
The Phase II Trial: What the Data Show
The defining clinical result for retatrutide is the Phase II trial published in the New England Journal of Medicine in 2023. The study randomised 338 adults with a body mass index of 30 or higher (or 27 or higher with at least one weight-related comorbidity) to retatrutide at 1, 4, 8, or 12 mg weekly, or to placebo, over a 48-week treatment period. The mean body weight reduction at 48 weeks in the 12 mg arm was a striking 24.2% — exceeding the 20.9% observed with tirzepatide 15 mg in SURMOUNT-1 and approaching the magnitude typically reported after sleeve gastrectomy.
The intermediate doses produced dose-dependent effects. The 8 mg arm achieved approximately 22.1% weight reduction; the 4 mg arm approximately 16.8%; and the 1 mg arm approximately 8.0%, broadly comparable to early-generation GLP-1R agonists. The proportion of participants in the 12 mg arm who achieved at least 5%, 10%, 15%, and 20% body weight reduction was 100%, 96%, 91%, and 75% respectively — unprecedented for any non-surgical intervention at any dose in any trial to date. The trial record and protocol are available on ClinicalTrials.gov.
Beyond weight, the Phase II trial reported meaningful improvements in cardiometabolic markers. Waist circumference fell by an average of 22 cm in the 12 mg arm. Triglycerides fell by approximately 30%. Systolic blood pressure fell by approximately 7 mmHg. HbA1c in the subset of participants with type 2 diabetes at baseline fell by more than 2 percentage points — comparable to tirzepatide in SURPASS-2 but at a lower dose. Liver fat content, assessed by MRI in a substudy, was reduced by more than 80% in the 12 mg arm, suggesting substantial benefit in metabolic dysfunction-associated steatotic liver disease (MASLD). The full metabolic dataset is reviewed on PMC.
Safety, Tolerability, and the Open Questions
Retatrutide's safety profile in the Phase II trial was broadly consistent with the GLP-1R agonist class. The most common adverse events were gastrointestinal: nausea, vomiting, diarrhoea, and constipation, predominantly during dose escalation and mostly mild to moderate in severity. Discontinuation rates due to adverse events were 6 to 16% across the active arms, compared with 0% on placebo. Heart rate increased modestly (by 3 to 7 beats per minute) at peak dose, mirroring the chronotropic effect seen with tirzepatide and semaglutide — a class effect whose long-term cardiovascular significance is still being characterised.
Two open questions dominate the next phase of investigation. First, the cardiovascular outcomes trial (TRIUMPH-CVOT) is now underway to determine whether the magnitude of weight and cardiometabolic improvement translates into reductions in major adverse cardiovascular events. Second, the durability question: weight regain after discontinuation of tirzepatide and semaglutide is well-documented, and there is no a priori reason to expect different behaviour with retatrutide. The peptide is suppressing appetite through defined receptor pathways; when the ligand is removed, the underlying biology reasserts itself. Long-term adherence, rather than short-term efficacy, may emerge as the rate-limiting factor in clinical translation. These questions are surveyed in a 2024 review on PubMed.
Retatrutide, Tirzepatide, and the Research Context at BioMuti
BioMuti supplies Retatrutide 30mg as a research-grade peptide vial, intended for laboratory and in-vitro research use. Each batch is independently tested by HPLC for purity (typically >98%) and by mass spectrometry for peptide identity, with a certificate of analysis provided. Retatrutide sits within a broader BioMuti research catalogue that includes Tirzepatide 30mg for dual-agonist studies, Semaglutide for GLP-1R-only comparisons, and MOTS-c for mitochondrial-derived peptide research — together forming the backbone of the metabolic peptide research toolkit.
As with all BioMuti research compounds, Retatrutide is sold strictly for research purposes. It has not been evaluated by SAHPRA for human therapeutic use in South Africa, and any clinical application of the research literature summarised above should be conducted under appropriate medical supervision and regulatory authorisation. Researchers and institutions requiring larger quantities can enquire about our wholesale programme, which offers tiered pricing and batch reservation services for established research teams.
The Broader Picture: Triple Agonism as a Design Principle
Retatrutide's results mark a transition point in peptide drug design. Where tirzepatide demonstrated that two incretin receptors could be co-engaged with additive benefit, retatrutide demonstrates that a third, mechanistically distinct receptor — the glucagon receptor — can be added without sacrificing tolerability. The same principle is now being applied beyond metabolism: dual amylin and calcitonin receptor agonists for weight, dual orexin receptor antagonists for sleep, biased mu-opioid agonists for analgesia. Class B1 GPCRs are particularly amenable to this kind of design because their peptide ligands share common structural motifs and can be hybridised at the sequence level without losing receptor engagement.
For South African researchers, retatrutide's emergence also raises practical questions about the local research landscape. Obesity prevalence in South Africa is among the highest in sub-Saharan Africa, and the burden of type 2 diabetes and MASLD is rising. Yet access to incretin-based research peptides has historically been limited by import complexity, regulatory uncertainty, and cost. BioMuti's local supply of research-grade tirzepatide, semaglutide, and retatrutide — manufactured and tested to consistent specifications — is one modest step toward closing that gap.
For readers interested in the wider context of metabolic peptide signalling, our articles on Tirzepatide and MOTS-c cover related research peptides with well-characterised mechanisms. The complete BioMuti research catalogue includes the full range of compounds discussed across the journal, all manufactured and tested to consistent research-grade specifications in South Africa.
Retatrutide is, in short, the first peptide to demonstrate that three metabolically relevant receptors can be engaged simultaneously in a single molecule with clinically meaningful benefit — and to do so at a magnitude that has forced the field to recalibrate what peptide-based metabolic interventions can accomplish. The next generation of triple and quadruple agonists is already in development, and the research tools for studying them are increasingly accessible to qualified investigators worldwide.
